Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
1.
J Exp Med ; 183(2): 705-10, 1996 Feb 01.
Article in English | MEDLINE | ID: mdl-8627186

ABSTRACT

Since tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and transforming growth factor (TGF)-beta have all been shown to be specific inhibitors of early human hematopoiesis, we wanted to investigate the interactions of these three cytokines on very primitive human adult bone marrow CD34++CD38- hematopoietic progenitor cells, using a pre-colony-forming cell (pre-CFC) assay, which detects the effects of these cytokines on the initial phases of the differentiation of these primitive progenitors, which are unresponsive to interleukin (IL) 3 alone. Surprisingly, TNF-alpha was a very potent stimulator of the proliferation of CD34++CD38- cells and was the most potent synergistic factor for the IL-3-induced proliferation of these cells of all cytokines tested (IL-1, IL-6, granulocyte colony-stimulating factor, kit ligand). TNF-alpha was the only cytokine that, as a single added factor, induced substantial proliferation in CD34++CD38- cells in the presence of IL-3, except for kit ligand, which induced very limited proliferation. TNF-alpha, moreover, induced a high degree of resistance to the inhibitory effects of TGF-beta in a dose-dependent way. The inhibitory effects of IFN-gamma, however, were not affected by the presence of TNF-alpha. We hypothesize that in situations of the hematopoietic stress, TNF-alpha may abrogate the inhibitory effect of ambient TGF-beta in the bone marrow microenvironment to allow primitive stem cells to proliferate and differentiate in response to an increased demand for mature blood cells.


Subject(s)
Antigens, CD , Hematopoietic Stem Cells/drug effects , Tumor Necrosis Factor-alpha/pharmacology , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Antigens, CD34 , Antigens, Differentiation , Bone Marrow Cells , Cell Differentiation , Cell Division , Cells, Cultured , Dose-Response Relationship, Drug , Drug Synergism , Humans , Membrane Glycoproteins , N-Glycosyl Hydrolases , Transforming Growth Factor beta/pharmacology
2.
J Exp Med ; 180(3): 1177-82, 1994 Sep 01.
Article in English | MEDLINE | ID: mdl-7520470

ABSTRACT

To assess the effects of interferon gamma (IFN-gamma) on very primitive hematopoietic progenitor cells, CD34(2+)CD38- human bone marrow cells were isolated and cultured in a two-stage culture system, consisting of a primary liquid culture phase followed by a secondary semisolid colony assay. CD34(2+)CD38- cells needed at least the presence of interleukin 3 (IL-3) and kit ligand (KL) together with either IL-1, IL-6, or granulocyte-colony-stimulating factor (G-CSF) in the primary liquid phase in order to proliferate and differentiate into secondary colony-forming cells (CFC). Addition of IFN-gamma to the primary liquid cultures inhibited cell proliferation and generation of secondary CFC in a dose-dependent way. This was a direct effect since it was also seen in primary single cell cultures of CD34(2+)CD38- cells. The proliferation of more mature CD34+CD38+ cells, however, was not inhibited by IFN-gamma, demonstrating for the first time that IFN-gamma is a specific and direct hematopoietic stem cell inhibitor. IFN-gamma, moreover, preserves the viability of CD34(2+)CD38- cells in the absence of other cytokines. IFN-gamma could, therefore, play a role in the protection of the stem cell compartment from exhaustion in situations of hematopoietic stress and may be useful as stem cell protecting agent against chemotherapy for cancer.


Subject(s)
Antigens, CD/analysis , Antigens, Differentiation/analysis , Hematopoietic Stem Cells/drug effects , Interferon-gamma/pharmacology , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Antigens, CD34 , Cell Differentiation/drug effects , Cell Division/drug effects , Cell Survival/drug effects , Hematopoietic Stem Cells/immunology , Hematopoietic Stem Cells/physiology , Humans , Membrane Glycoproteins
3.
mBio ; 10(3)2019 05 07.
Article in English | MEDLINE | ID: mdl-31064833

ABSTRACT

Infectious viruses so precisely fit their hosts that the study of natural viral infection depends on host-specific mechanisms that affect viral infection. For human parainfluenza virus 3, a prevalent cause of lower respiratory tract disease in infants, circulating human viruses are genetically different from viruses grown in standard laboratory conditions; the surface glycoproteins that mediate host cell entry on circulating viruses are suited to the environment of the human lung and differ from those of viruses grown in cultured cells. Polarized human airway epithelium cultures have been used to represent the large, proximal airways of mature adult airways. Here we modeled respiratory virus infections that occur in children or infect the distal lung using lung organoids that represent the entire developing infant lung. These 3D lung organoids derived from human pluripotent stem cells contain mesoderm and pulmonary endoderm and develop into branching airway and alveolar structures. Whole-genome sequencing analysis of parainfluenza viruses replicating in the organoids showed maintenance of nucleotide identity, suggesting that no selective pressure is exerted on the virus in this tissue. Infection with parainfluenza virus led to viral shedding without morphological changes, while respiratory syncytial virus infection induced detachment and shedding of infected cells into the lung organoid lumens, reminiscent of parainfluenza and respiratory syncytial virus in human infant lungs. Measles virus infection, in contrast, induced syncytium formation. These human stem cell-derived lung organoids may serve as an authentic model for respiratory viral pathogenesis in the developing or infant lung, recapitulating respiratory viral infection in the host.IMPORTANCE Respiratory viruses are among the first pathogens encountered by young children, and the significant impact of these viral infections on the developing lung is poorly understood. Circulating viruses are suited to the environment of the human lung and are different from those of viruses grown in cultured cells. We modeled respiratory virus infections that occur in children or infect the distal lung using lung organoids that represent the entire developing infant lung. These 3D lung organoids, derived from human pluripotent stem cells, develop into branching airway and alveolar structures and provide a tissue environment that maintains the authentic viral genome. The lung organoids can be genetically engineered prior to differentiation, thereby generating tissues bearing or lacking specific features that may be relevant to viral infection, a feature that may have utility for the study of host-pathogen interaction for a range of lung pathogens.


Subject(s)
Alveolar Epithelial Cells/virology , Lung/virology , Organoids/virology , Parainfluenza Virus 3, Human/pathogenicity , Pluripotent Stem Cells/virology , Respirovirus Infections/pathology , Cell Differentiation , Cells, Cultured , Genome, Viral , Humans , Infant , Lung/cytology , Lung/pathology , Measles virus/pathogenicity , Parainfluenza Virus 3, Human/genetics , Respiratory Syncytial Virus, Human/pathogenicity , Virus Internalization , Whole Genome Sequencing
4.
J Clin Invest ; 103(6): 859-67, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10079107

ABSTRACT

The interaction of the T-cell receptor with the major histocomatibility complex (MHC)-peptide complex is central to T-cell activation. Variation in the nature of the peptide bound within the groove of the MHC molecule may result in an altered T-cell response. Because some naturally processed peptides bound within the groove of the class II MHC molecule are derived from the MHC molecules themselves, we studied the inhibitory effects of synthetic class II MHC peptides on alloimmune responses in vitro. Three peptides derived from a highly conserved region of the class II MHC alpha chains inhibited the rat mixed lymphocyte response (MLR) in a dose-dependent manner, with the human HLA-DQA1 peptide also inhibiting the human and mouse MLR. No effect was seen on mitogen-induced T-cell proliferation. HLA-DQA1 inhibited cytolytic T lymphocyte (CTL) generation in a dose-response fashion, with no reduction in preformed CTL killing, suggesting that the inhibitory effect is targeted at CD4(+) T-cell function. Cell-cycle analysis by flow cytometry showed that restimulation of primed T cells in the presence of HLA-DQA1 resulted in increased apoptosis, whereas unstimulated cells were not affected. These data demonstrate that synthetic peptides derived from highly conserved regions of the class II MHC alpha chain can alter CD4(+) T-lymphocyte alloimmune responses in vitro, and this effect is mediated by the induction of apoptosis in activated T cells.


Subject(s)
Apoptosis/immunology , CD4-Positive T-Lymphocytes/immunology , Histocompatibility Antigens Class II/immunology , Isoantigens/immunology , Adjuvants, Immunologic , Amino Acid Sequence , Animals , Antigen Presentation , Conserved Sequence , Cytotoxicity, Immunologic , HLA-DQ Antigens/immunology , HLA-DQ alpha-Chains , Histocompatibility , Humans , Interferon-gamma/biosynthesis , Interleukin-2/biosynthesis , Lymphocyte Activation , Lymphocyte Culture Test, Mixed , Mice , Molecular Sequence Data , Peptide Fragments/immunology , Rats
5.
Leukemia ; 7(4): 625-9, 1993 Apr.
Article in English | MEDLINE | ID: mdl-7681919

ABSTRACT

We studied the effects of interleukin 4 (IL4) on myelopoiesis supported by either granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF) or IL3 on purified CD34+ bone marrow progenitor cells. IL4 stimulates the colony-forming unit granulocyte (CFU-G) induced by G-CSF and inhibits all colony types supported by either IL3 and GM-CSF, although inhibition of CFU-M (macrophage) was significantly stronger than that of CFU-G and CFU-GM. When the cells were first incubated in liquid culture for 4 days in IL4, followed by agar culture in G-CSF, there was a significant increase in the number of CFU-G compared to cells which had been incubated in medium alone for 4 days before plating out in agar containing G-CSF. The inhibitory effects of IL4 on GM-CSF or IL3 supported colony formation, however, disappear with sequential incubation in IL4 in liquid culture followed by culture in agar with either GM-CSF or IL3.


Subject(s)
Antigens, CD , Bone Marrow/drug effects , Hematopoietic Stem Cells/drug effects , Interleukin-4/pharmacology , Antigens, CD34 , Bone Marrow Cells , Cells, Cultured , Dose-Response Relationship, Drug , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Humans , Recombinant Proteins/pharmacology , Time Factors
6.
Leukemia ; 10(1): 117-22, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8558915

ABSTRACT

We have previously shown that interleukin 4 (IL-4) and interferon gamma (INF-gamma) reciprocally regulate the production of granulocytes and monocytes from mature monopotential hematopoietic progenitor cells, while at the level of the very primitive stem cells IFN-gamma is a selective inhibitor of proliferation and differentiation, and IL-4 has weak stimulatory effects. We investigated the effects of IL-4 and IFN-gamma on the expansion in suspension culture of myeloid colony-forming cells (CFCs) induced by either IL-3 or IL-1+IL-3, using on the one hand more differentiated CD34+HLA-DR strongly positive (HLA-DR++) and on the other hand more primitive Cd34+HLA-DR weakly positive (HLA-DR+/-) human bone marrow cells. It is shown that both IL-4 and IFN-gamma stimulate the IL-3- and IL-3+IL-1-induced expansion of the number of CFCs in the HLA-DR+/- population. In the presence, but not in the absence of IL-1, additive effects of IL-4 and IFN-gamma were seen. We could not demonstrate any IL-3-like effect by IL-4 on early human hematopoietic progenitors. No expansion of CFC number was seen in the HLA-DR++ population. Based on these data and on data which we have published previously, a model for the regulation of myelopoiesis by IL-4 and IFN-gamma is proposed. In this model, IL-4 and IFN-gamma, which are both immune recognition induced inflammatory cytokines, both stimulate the expansion and recruitment of early myeloid progenitors, whereas at the level of their terminal differentiation, the balance between both cytokines determines whether preferentially monocytes/macrophages (IFN-gamma) or granulocytes (IL-4) are being produced. At the level of the most primitive cells, the inhibitory action of IFN-gamma might prevent differentiative exhaustion of the stem cell compartment in situations of hematopoietic stress.


Subject(s)
Bone Marrow Cells , Hematopoietic Stem Cells/cytology , Interferon-gamma/pharmacology , Interleukin-4/pharmacology , Antibody Formation , Antigens, CD34/metabolism , Cell Differentiation , Cell Division , Cells, Cultured , Drug Synergism , HLA-DR Antigens/metabolism , Hematopoietic Stem Cells/immunology , Humans , Immunity, Cellular , Interleukin-1/pharmacology , Interleukin-3/pharmacology , Models, Biological
7.
Leukemia ; 10(12): 1937-43, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8946934

ABSTRACT

We investigated the cell kinetic effects of retinoic acid (RA) and the functional interaction between RA and TGF-beta on normal human bone marrow progenitor cells (CD34+). Cell cycle progression throughout the first three consecutive cell cycles and alterations in cell kinetic responses were measured using the BrdU-Hoechst quenching technique. RA stimulates the IL-3-induced growth by additionally recruiting quiescent stem and progenitor cells out of the G0/G1-phase and by increasing the cell cycle traverse rate. In contrast, TGF-beta addition resulted in a significant decrease in the number of proliferating cells. Simultaneous addition of RA and TGF-beta resulted in a stronger inhibition compared to addition of TGF-beta alone. Preincubation experiments further showed that RA is capable of sensitizing the progenitors to the inhibitory action of TGF-beta: the inhibitory effect of TGF-beta was significantly increased when cells were pretreated with RA. These data show that, in combination with IL-3, RA additionally stimulates quiescent bone marrow progenitors in a simultaneous way, and that it increases sensitivity of the progenitors to the inhibitory action of TGF-beta. The combination of RA and TGF-beta on normal and leukemic hematopoiesis has to be further investigated, since this combination may possibly provide additional therapeutic benefit.


Subject(s)
Antineoplastic Agents/pharmacology , Bone Marrow Cells , Bone Marrow/drug effects , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/drug effects , Transforming Growth Factor beta/pharmacology , Tretinoin/pharmacology , Antigens, CD34/analysis , Bromodeoxyuridine/metabolism , Cell Cycle/drug effects , Cell Division/drug effects , Drug Interactions , Ethidium , Flow Cytometry/methods , G1 Phase/drug effects , Humans , Interleukin-3/pharmacology , Resting Phase, Cell Cycle/drug effects , Sensitivity and Specificity
8.
Leukemia ; 13(8): 1266-72, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10450756

ABSTRACT

Important functional differences exist between primitive CD34++ CD38- hematopoietic progenitor cells derived from human fetal liver (FL) and adult bone marrow (ABM). FL progenitors are known to have higher proliferative capacities and lower cytokine requirements than their ABM counterparts. In this study, we isolated FL and ABM CD34++ CD38- cells and used a two-stage culture system to investigate the effects of transforming growth factor-beta (TGF-beta) and blocking anti-TGF-beta antibodies (anti-TGF-beta) on these cells. First, we demonstrate that FL progenitors are significantly less sensitive to the inhibitory effects of TGF-beta than ABM cells. Second, whereas ABM cells are significantly stimulated by anti-TGF-beta, only very limited effects are seen on FL cells. Third, we show that the effect of anti-TGF-beta is mainly situated at the level of the initial cell cycles of very primitive progenitor cells with a high proliferation potential. Fourth, we demonstrate that blocking the effects of endogenous TGF-beta reduces the growth factor requirements of ABM cells in order to proliferate and differentiate. Based on these data, we hypothesize that at least part of the functional differences that exist between adult and fetal stem cells can be accounted for by a developmental different responsiveness to TGF-beta.


Subject(s)
Hematopoietic Stem Cells/drug effects , Hematopoietic Stem Cells/physiology , Transforming Growth Factor beta/pharmacology , Adult , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cell Division/drug effects , Cells, Cultured , Female , Fetus/cytology , Fetus/physiology , Hematopoietic Stem Cells/cytology , Humans , Pregnancy
9.
Exp Hematol ; 21(11): 1480-6, 1993 Oct.
Article in English | MEDLINE | ID: mdl-7691636

ABSTRACT

We studied the effects of interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) on the expression of CD38 and human leukocyte antigen (HLA)-DR on purified CD34+ bone marrow progenitor cells. CD34+CD38- and CD34+HLA-DR- cells are largely nonoverlapping populations. After culture for 4 days in IFN-gamma, the expression of CD38 and HLA-DR is significantly increased and the disappearance of the CD38- and HLA-DR- populations is virtually complete. Moreover, IFN-gamma induces a population of CD34+ cells with a very high expression of CD38 (CD34+CD38++ cells), which were absent in the initial CD34+ population. IL-4 has no effect on the expression of CD38, but induces a limited but significant increase in the expression of HLA-Dr. After culture in IFN-gamma, CD34+ cells show a higher cloning efficiency of the colony-forming unit-macrophage (CFU-M) and burst-forming unit-erythroid (BFU-E) compared to cells cultured in medium alone. After culture in IL-4, a limited increase in CFU-granulocyte (CFU-G) and BFU-E is seen, whereas CFU-G, CFU-M, and BFU-E are increased after culture in IL-4 plus IFN-gamma. We further investigated the functional properties of the CD34+CD38++ cells generated in the presence of IFN-gamma. This cell population is highly enriched for BFU-E but partially depleted of CFU-M. Most of the CFU-M were found in the CD34+CD38+/-(CD34+CD38- and CD34+CD38+ cells) population.


Subject(s)
Antigens, CD/analysis , Antigens, Differentiation/biosynthesis , HLA-DR Antigens/biosynthesis , Hematopoietic Stem Cells/immunology , Interferon-gamma/pharmacology , Interleukin-4/pharmacology , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Antigens, CD34 , Cells, Cultured , Clone Cells , Colony-Forming Units Assay , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/drug effects , Humans , Membrane Glycoproteins , Recombinant Proteins/pharmacology
10.
Exp Hematol ; 21(5): 635-9, 1993 May.
Article in English | MEDLINE | ID: mdl-7685706

ABSTRACT

We compared the myelopoietic effects of interleukin-4 (IL-4) on CD34+HLA-DR+ and on CD34+HLA-DR++ bone marrow progenitor cells stimulated by either granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3). IL-4 stimulates G-CSF-induced colony-forming unit-granulocyte (CFU-G) and inhibits all colony types induced by GM-CSF and IL-3 in the HLA-DR++ population, but not in the HLA-DR+ population. In CD34+HLA-DR+ cells, however, a stimulation of G-CSF-supported CFU-G was also seen with sequential application of IL-4 in liquid cultures followed by G-CSF in agar cultures. In order to confirm that these are direct effects of IL-4, single-cell culture experiments were performed with CD34+HLA-DR++ cells. In these cultures IL-4 stimulates G-CSF-induced CFU-G and only inhibits colony-forming unit-macrophage (CFU-M) regardless of the CSF used to generate them.


Subject(s)
Antigens, CD/analysis , Granulocytes/cytology , HLA-DR Antigens/analysis , Hematopoiesis , Interleukin-4/pharmacology , Antigens, CD34 , Bone Marrow Cells , Cells, Cultured , Drug Synergism , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Granulocytes/immunology , Humans , Interleukin-3/pharmacology
11.
Exp Hematol ; 24(13): 1509-15, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8950234

ABSTRACT

We investigated the effects of transforming growth factor-beta (TGF-beta) and macrophage inflammatory protein-1 alpha (MIP-1 alpha) on very primitive CD34++CD38- and on more mature CD34++CD38+ human hematopoietic progenitor cells by means of a two stage pre-colony-forming cell (pre-CFC) assay. The first (liquid) stage of this assay allows evaluation of the effects of TGF-beta and MIP-1 alpha on the "primary" proliferation of the progenitors under study and on the generation of "secondary" colony-forming cells (CFC, cells for which a second stage semisolid clonogenic assay was used as a read-out). TGF-beta inhibited the proliferation and CFC generation of CD34++CD38- and CD34+CD38+ cells, showing the strongest inhibitory activity on CD34++CD38- cells. MIP-1 alpha exerted a weaker inhibitory activity on CD34+2CD38- cells, whereas it enhanced the primary proliferation of CD34+CD38+ cells and generation of secondary CFC in this subpopulation. Thus, TGF-beta, and MIP-1 alpha both inhibit very primitive CD34+2)CD38- cells, but they are not equally potent. The effects of TGF-beta and MIP-1 alpha on more mature progenitor cells are more complex. Our results and data from the literature indicate that, as progenitor cells mature, they reach a "pivotal point" at a certain stage in their differentiation pathway, depending on the inhibitor, where they are no longer inhibited or where they may even be stimulated by the former inhibitor to proliferate.


Subject(s)
Antigens, CD34/analysis , Antigens, CD , Antigens, Differentiation/analysis , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/immunology , Macrophage Inflammatory Proteins/pharmacology , N-Glycosyl Hydrolases/analysis , Transforming Growth Factor beta/pharmacology , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Cell Cycle/drug effects , Cells, Cultured , Chemokine CCL4 , Humans , Membrane Glycoproteins
12.
Exp Hematol ; 22(9): 903-9, 1994 Aug.
Article in English | MEDLINE | ID: mdl-7520393

ABSTRACT

The immediate cell kinetic response of highly purified human bone marrow progenitor cells (CD34+ sorted fraction) to the inhibitory effects of transforming growth factor-beta (TGF-beta) was studied using the BrdU-Hoechst flow-cytometric technique. The progenitor cells were stimulated with either interleukin-3 (IL-3) alone or with IL-3 in combination with IL-1, stem cell factor (SCF), or IL-6, and the inhibitory action of TGF-beta was evaluated in each phase of the first three consecutive cell cycles. Semisolid methylcellulose cultures were also performed to compare these initial events to the effects observed after 7, 14, and 21 days of incubation. Within the CD34+ compartment, the progenitor cells can be discriminated on a functional basis, i.e., in terms of TGF-beta sensitivity. Very primitive progenitors, recruited out of the G0 phase by IL-3 plus an early-acting factor (IL-1, SCF) are, upon addition of TGF-beta, arrested specifically in the G1 phase of the second cell cycle. In the clonogenic assays, the increased colony formation due to IL-1 or SCF was completely abolished by the counteracting effect of TGF-beta that diminished colony output back to the level of TGF-beta-plus-IL-3 supplemented colony growth. Addition of TGF-beta to CD34+ progenitors responding to IL-3 alone resulted in an overall retardation, but without an apparent specific accumulation of cells in any of the cell cycles. Finally, within the CD34+ compartment, there exists a subset of IL-3-responsive, but TGF-beta-insensitive, progenitor cells that were, upon addition of TGF-beta, not arrested at all. In conclusion, our results demonstrate that TGF-beta exerts different cell kinetic effects on CD34+ progenitor cell growth depending on the applied stimulus.


Subject(s)
Antigens, CD/analysis , Hematopoietic Cell Growth Factors/pharmacology , Hematopoietic Stem Cells/cytology , Interleukin-1/pharmacology , Interleukin-3/pharmacology , Interleukin-6/pharmacology , Transforming Growth Factor beta/pharmacology , Antigens, CD34 , Cell Cycle/drug effects , Cell Division/drug effects , Cells, Cultured , Drug Interactions , Flow Cytometry , Fluorescence , Hematopoietic Stem Cells/drug effects , Humans , Stem Cell Factor
13.
Exp Hematol ; 26(11): 1034-42, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9766443

ABSTRACT

CD34++ CD38- and CD34+ CD38+ hematopoietic progenitor cells (HPCs) from human fetal liver (FL), cord blood (CB), and adult bone marrow (ABM) were isolated and investigated for their growth characteristics, cytokine requirements and response to two modulators of early hematopoiesis, interferon (IFN)-gamma and macrophage inflammatory protein (MIP)-1alpha. We observed first that a significantly lower percentage of CD34++ cells were CD38- in ABM than in FL and CB. Second, the functional differences between CD34++ CD38- and CD34+ CD38+ cells were less pronounced in FL and CB than in their ABM counterparts. Third, an inverse correlation was found between growth factor response and the ontogenic age of HPCs, and a direct correlation was noted between cytokine requirements and the ontogenic age of HPCs. Fourth, spontaneous colony formation in a classic semisolid culture system was reproducibly obtained only in the ontogenically earliest cells, that is, in FL but not in CB and ABM, in which no such spontaneous colony formation was observed. Fifth, the modulatory effects of IFN-gamma and MIP-1alpha were qualitatively different depending on the ontogenic age of the progenitor source: whereas IFN-gamma was only a selective inhibitor of primitive CD34++ CD38- ABM progenitor cells, it inhibited both CD34++ CD38- and CD34+ CD38+ FL and CB cells to the same extent. In contrast to the effects of MIP-1alpha on ABM, we could not find any consistently stimulatory or inhibitory effects on FL and CB progenitors. In conclusion, important functional and biologic differences exist between FL, CB, and ABM progenitor cells, and these differences could have major implications for the use of these cell populations in preparative protocols of ex vivo expansion, transplantation strategies, or gene transfer experiments.


Subject(s)
Antigens, CD/blood , Bone Marrow/immunology , Cytokines/pharmacology , Fetal Blood/immunology , Hematopoietic Stem Cells/immunology , Liver/immunology , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Adult , Antigens, CD34/blood , Antigens, Differentiation/blood , Bone Marrow/embryology , Cell Division/immunology , Cells, Cultured , Chemokine CCL3 , Chemokine CCL4 , Colony-Forming Units Assay , Embryonic and Fetal Development/physiology , Humans , Interferon-gamma/pharmacology , Liver/embryology , Macrophage Inflammatory Proteins/pharmacology , Membrane Glycoproteins , NAD+ Nucleosidase/blood
14.
AJNR Am J Neuroradiol ; 18(10): 1935-8, 1997.
Article in English | MEDLINE | ID: mdl-9403457

ABSTRACT

Treatment of acute renal allograft rejection with mouse monoclonal antibody (OKT3) is associated with systemic and neurologic side effects. We describe cerebral abnormalities in a 13-year-old boy with steroid-resistant renal allograft rejection. After treatment with OKT3, an acute neurologic syndrome developed, including seizures, lethargy, and decreased mental function. CT and MR imaging revealed confluent cerebral lesions at the corticomedullary junction. Contrast-enhanced MR images showed patchy enhancement, indicating blood-brain barrier dysfunction. The diagnosis of OKT3-induced encephalopathy with cerebral edema and capillary leak syndrome was made. Although CT and MR findings are nonspecific, neuroradiologists should be aware of this condition in transplant patients treated with OKT3.


Subject(s)
Brain Damage, Chronic/chemically induced , Brain/drug effects , Graft Rejection/drug therapy , Kidney Transplantation , Magnetic Resonance Imaging , Muromonab-CD3/adverse effects , Tomography, X-Ray Computed , Adolescent , Animals , Blood-Brain Barrier/drug effects , Brain/pathology , Brain Damage, Chronic/diagnosis , Brain Edema/chemically induced , Brain Edema/diagnosis , Capillary Leak Syndrome/chemically induced , Capillary Leak Syndrome/diagnosis , Humans , Iatrogenic Disease , Male , Mice , Muromonab-CD3/administration & dosage
16.
Exp Nephrol ; 5(6): 514-20, 1997.
Article in English | MEDLINE | ID: mdl-9438181

ABSTRACT

There are several obstacles that prevent the successful clinical application of gene therapy. Some of these challenges are unique to the particular disease and organ that is being targeted. Desirable characteristics of approaches aimed at delivery of a therapeutic gene to the kidney ideally will require a vector that is safe, that efficiently transduces nondividing cells, and that can lead to long-term gene expression. Viral vectors that are derived from the small replication-deficient parvovirus, adeno-associated virus, offer many potential advantages. The wild-type virus is nonpathogenic and can site specifically integrate at a single location on chromosome 19, a process that offers the hope that this characteristic could be engineered into recombinant vectors as well. Recombinant adeno-associated virus can also efficiently integrate into the host genome, can transduce nondividing cells, and does not induce an immune response which destroys the transduced cells. Efforts focused both on gaining a more complete understanding of the virus life cycle as well on the efficient production of high-titer virus should bring this vector closer to clinical application.


Subject(s)
Dependovirus/genetics , Genetic Vectors , DNA, Recombinant , Gene Transfer Techniques , Humans
17.
Blood ; 81(12): 3211-6, 1993 Jun 15.
Article in English | MEDLINE | ID: mdl-7685198

ABSTRACT

The bromodeoxyuridine (BrdU)-Hoechst flow cytometric technique was applied to study the immediate cell kinetic response of highly purified human (h) bone marrow progenitor cells (CD(34+)-sorted fraction) to h granulocyte colony-stimulating factor (G-CSF) and/or h granulocyte-macrophage colony-stimulating factor (GM-CSF). The technique permits us to differentiate cycling from noncycling cells and to make a quantitative assessment of cell cycles after stimulation. Semisolid agar and single-cell liquid cultures were also performed to compare these initial events to the effects observed after 14 days of culture. The combination of G-CSF plus GM-CSF, acting synergistically in day 14 cultures, was found to have a subadditive effect in the first cell cycles, thereby indicating partial overlap of the different target cells. However, this combination accelerated transit through the cell cycle, as could be seen from the higher number of cells in the third cell cycle after 72 hours of stimulation. We conclude that, apart from the unresponsive cells, the CD34+ compartment consists of cells responsive to both G-CSF and GM-CSF, and cells responsive to either one of the CSFs alone, and that the combination of the two CSFs speeds up the cell cycle traverse rate for a significant fraction of the target cells that are initially responsive for both G-CSF and GM-CSF. The latter supports the hypothesis of an overlapping signalling pathway of G-CSF and GM-CSF.


Subject(s)
Antigens, CD/analysis , Bone Marrow Cells , Cell Cycle , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Antigens, CD34 , Bisbenzimidazole , Bone Marrow/immunology , Bromodeoxyuridine , Cell Division , Cells, Cultured , DNA/biosynthesis , Drug Synergism , Ethidium , Flow Cytometry , Humans , Staining and Labeling
18.
Ann Hematol ; 76(3-4): 179-81, 1998.
Article in English | MEDLINE | ID: mdl-9619737

ABSTRACT

Cytomegalovirus encephalitis is a rare but life-threatening infection in non-AIDS patients. To our knowledge, no case that followed conventional treatment for Hodgkin's lymphoma has been reported. We present a patient with Hodgkin's disease in complete remission after combined modality treatment who was succesfully treated with a combination of ganciclovir and foscarnet.


Subject(s)
Antiviral Agents/therapeutic use , Cytomegalovirus Infections/drug therapy , Cytomegalovirus Infections/etiology , Encephalitis, Viral/drug therapy , Encephalitis, Viral/etiology , Foscarnet/therapeutic use , Ganciclovir/therapeutic use , Hodgkin Disease/complications , Hodgkin Disease/therapy , Combined Modality Therapy/adverse effects , Female , Hodgkin Disease/pathology , Humans , Middle Aged , Remission Induction
19.
Eur J Immunol ; 23(5): 1072-7, 1993 May.
Article in English | MEDLINE | ID: mdl-7682957

ABSTRACT

We studied the direct effects of interferon-gamma (IFN-gamma) in single cell colony assays of CD34+HLA-DR++ bone marrow progenitor cells stimulated by either granulocyte-colony-stimulating factor (G-CSF), interleukin(IL)-3, granulocyte/macrophage-colony-stimulating factor (GM-CSF), combinations of these CSF or medium conditioned by the 5637 human bladder carcinoma cell line. In this culture system IFN-gamma stimulated monocytic colonies (CFU-M) no matter which CSF or CSF combination was used to support them and inhibited granulocytic colonies (CFU-G) if they were generated in the presence of G-CSF. IL-4 antagonized the myelopoietic effects of IFN-gamma: the IFN-gamma-induced suppression of G-CSF-supported CFU-G, as well as the stimulation of CFU-M, were reversed by IL-4. In all cultures, IFN-gamma had a limited, but statistically non-significant, inhibitory effect on CFU-GM, which was not affected by the presence of IL-4. These data show that IFN-gamma and IL-4 reciprocally regulate the generation of myeloid cells involved in humoral (neutrophils) and cellular (macrophages) immune responses through a direct effect on monopotential myeloid progenitor cells.


Subject(s)
Hematopoietic Stem Cells/drug effects , Interferon-gamma/pharmacology , Interleukin-4/pharmacology , Macrophages/drug effects , Monocytes/drug effects , Neutrophils/drug effects , Animals , Granulocyte Colony-Stimulating Factor/pharmacology , Hematopoiesis/drug effects , Hematopoietic Stem Cells/physiology , Humans , Interferon-gamma/antagonists & inhibitors , Macrophages/physiology , Mice , Monocytes/physiology , Neutrophils/physiology , Rabbits
20.
Ann Hematol ; 66(2): 61-6, 1993 Feb.
Article in English | MEDLINE | ID: mdl-7680579

ABSTRACT

The effects of both 13-cis-and all-trans retinoic acid (RA) on colony formation of normal bone marrow (BM) progenitors were investigated in semi-solid (methylcellulose) assays, using either isolated CD34+ cells or BM mononuclear cells. Single cell liquid cultures were performed to further discriminate between direct and indirect effects. RA action results in significant decrease of colony forming units (CFUs). This effect is more pronounced starting from CD34+ progenitors than starting from total BM. This overall decrease in CFUs is due to selective inhibition of CFU-M (macrophage) and erythroid colonies (BFU-E). At the single cell level the CFU-M inhibition is confirmed with--in addition--a significant inhibition of CFU-GM (granulocyte-macrophage) and a marked stimulation of CFU-G (granulocyte)s. Both retinoids exert the above-mentioned effects. All-trans RA, however, is effective at a tenfold lower concentration (10(-7)M) than 13-cis RA (10(-6)M). Results on CD34+ BM fractions (substantially reduced in accessory cells) demonstrate that the described effects can probably be attributed to the direct action of RA on these progenitors; single progenitor (CD34+) cell liquid cultures further prove this point.


Subject(s)
Bone Marrow Cells , Hematopoietic Stem Cells/cytology , Tretinoin/pharmacology , Antigens, CD/analysis , Antigens, CD34 , Cell Count , Clone Cells/cytology , Erythroid Precursor Cells/cytology , Granulocytes/cytology , Hematopoietic Stem Cells/immunology , Humans , Macrophages/cytology , Tretinoin/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL